欧洲初创Orbis药品筹集93M万美元, 用于研发创新口服药物, European startup Orbis Medicines raises $93M to develop innovative oral drugs, challenging injectables.

Orbis药物是欧洲生物技术的启动项目,已筹募9 300万美元用于研制口服Peptide药物,称为宏观循环。 Orbis Medicines, a European biotech startup, has raised $93 million to develop oral peptide drugs known as macrocycles. 这些药物旨在将传统医药和生物医学的好处结合起来,改善病人的方便。 These drugs aim to combine the benefits of traditional medicines and biologics, improving patient convenience. 该公司的技术可以迅速生产多达100 000种大型环环化合物,针对目前用注射药物治疗的疾病。 The company's technology can produce up to 100,000 macrocyclic compounds quickly, targeting diseases currently treated with injectable drugs. 投资者包括Eli Lilly和Novo Holdings,预计生物市场到2034年将大幅增长。 Investors include Eli Lilly and Novo Holdings, with the market for biologics expected to grow significantly by 2034.